- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Grants 510(k) Clearance for Novel Endoscopic Ultrasound Device
The EndoSound Vision System reportedly enables providers to convert existing upper gastrointestinal endoscopes into endoscopic ultrasound modalities.
The Food and Drug Administration (FDA) has cleared the EndoSound Vision System (EndoSound), a modality that may help broaden access to endoscopic ultrasound for gastrointestinal diseases.
EndoSound said the EndoSound Vision System (EVS) can be attached to existing upper gastrointestinal endoscopes. While the company noted that 95 percent of endoscopic ultrasound services are performed in hospital settings, it maintained that the “more economical” EVS may allow more use of the technology in ambulatory care settings.
While 95 percent of endoscopic ultrasound services are reportedly performed in hospital settings, EndoSound maintained that its recently FDA-cleared and “more economical” EndoSound Vision System (shown above) may allow more use of the technology in ambulatory care settings.
The EndoSound Vision System, which previously garnered an FDA Breakthrough Device Designation in July 2021, provides detailed gastrointestinal imaging, and also addresses the issue of infections that may occur with endoscope elevators that are difficult to clean, according to EndoSound.
“This (FDA clearance) milestone underscores our commitment to advancing medical technology and improving patient outcomes. With the EVS, we aim to not only enhance the safety of endoscopic procedures but also contribute to expanding access to care for patients worldwide,” noted Stephen Steinberg, M.D., the president and CEO of EndoSound.
(Editor’s note: For related content, see “Endoscopic Ultrasound Biopsy Modality Gets FDA Nod” and “AI-Powered Liver Tumor Ablation Software Leverages CT, MRI and Ultrasound for Real-Time Image Guidance” and “Diagnostic Imaging’s Top Five Ultrasound Content of 2023.”)
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
